Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Physiological, patho-physiological, and potential therapeutic roles for neutrophils in cancer & beyond.

Frontiers in immunology·2026

Same author

Neurobiological pathways underlying brain tumor progression: basis for oncogenicity and opportunities for immunotherapeutic intervention.

Frontiers in oncology·2026

Same author

The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity.

Cancer immunology research·2025

Same author

Innate iNKT cells: from biological insight to clinical impact.

Frontiers in immunology·2025

Same author

CAR-iNKT cells: redefining the frontiers of cellular immunotherapy.

Frontiers in immunology·2025

Same author

Broad applicability of the Goldspire™ platform for the treatment of solid tumors.

Clinical immunology (Orlando, Fla.)·2024

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

CD1d activation and blockade: a new antitumor strategy.

Michele W L Teng¹, Simon Yue, Janelle Sharkey

¹Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

Journal of Immunology (Baltimore, Md. : 1950)

|March 7, 2009

Summary

Anti-CD1d monoclonal antibodies (mAbs) inhibit tumor growth by activating antigen-presenting cells (APCs) and producing key cytokines. This immunotherapy approach shows promise for various cancers.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Experiment Videos

Last Updated: Jun 25, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Area of Science:

Immunology
Oncology
Cancer Research

Background:

CD1d molecules on antigen-presenting cells (APCs) present glycolipids to CD1d-restricted natural killer T (NKT) cells.
The role of CD1d in anti-tumor immunity is an area of active investigation.

Purpose of the Study:

To investigate the efficacy of anti-CD1d monoclonal antibodies (mAbs) in inhibiting the growth of experimental carcinomas.
To elucidate the mechanisms underlying anti-CD1d mAb-mediated tumor suppression.

Main Methods:

Treatment of mice bearing CD1d-negative experimental carcinomas with anti-CD1d mAbs.
Assessment of APC activation through interferon-gamma (IFN-γ) and interleukin-12 (IL-12) production.
Evaluation of the roles of CD8(+) T cells, NK cells, and regulatory NKT cells in tumor growth inhibition.

Main Results:

Anti-CD1d mAbs demonstrated significant inhibition of tumor growth in CD1d-negative experimental carcinomas.
Systemic activation of CD1d(+) APCs was observed, leading to increased IFN-γ and IL-12 production.
Tumor growth inhibition was dependent on IFN-γ and IL-12, with variable contributions from CD8(+) T cells and NK cells depending on the tumor model.
The efficacy of anti-CD1d mAbs was influenced by the presence of regulatory CD1d-restricted type II NKT cells and immunosuppressive regulatory T cells.

Conclusions:

Anti-CD1d mAbs represent a novel therapeutic strategy for cancer immunotherapy by modulating tumor immunity.
The dual action of anti-CD1d mAbs in activating APCs and modulating NKT cell activity offers a promising avenue for cancer treatment.